Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atara Biotherapeutics (GB:0HIY)
LSE:0HIY
RESEARCH TOOLSreports
Atara Biotherapeutics (0HIY) Share Price & Analysis
1 Followers
0HIY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.20 - $3.08
Previous Close$0.68
Volume1.83K
Average Volume (3M)46.85K
Market Cap
$81.00M
Enterprise Value$27.10M
Total Cash (Recent Filing)$102.41M
Total Debt (Recent Filing)$48.51M
Price to Earnings (P/E)N/A
Beta2.51
Next Earnings
May 08, 2024EPS Estimate
-$0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding119,359,230
10 Day Avg. Volume1,002
30 Day Avg. Volume46,846
Standard Deviation0.20
R-Squared0.26
Alpha0.00532
Financial Highlights & Ratios
Price to Book (P/B)-1.59
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.76
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$5.43Price Target Upside699.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Atara Biotherapeutics News
PremiumCompany Announcements
Atara Biotherapeutics Board Member Decides Not to Seek Re-Election
PremiumCompany Announcements
Atara Biotherapeutics Restructures, CMO Transitions to Consultant
Bulls Say, Bears Say
Bulls Say
Financial ForecastVarious CAR-T products, with likely the next key inflection coming from ATA3219, are projected to contribute to a robust CAR-T platform, potentially reaching up to $1Bn in peak sales.
PartnershipAtara receives meaningful upfront cash in connection with the closure of the expanded global partnership with Pierre Fabre.
Regulatory MilestoneConcordance with U.S. regulators on tab-cel BLA requirements supports Atara's ability to pool the pivotal clinical trial data.
Bears Say
Clinical Trial OutcomeThe trial failed, with no discernible trend, suggesting a worst-case scenario outcome.
Financial HealthDespite cash reserves from the Pierre Fabre deal, investor confidence may wane due to ongoing operational expenditures and a tough market environment.
Regulatory RiskRisks include, but are not limited to: rejection of the tab-cel BLA by the FDA.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
19.05% Other Institutional Investors
80.95% Public Companies and
Individual Investors
0HIY FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest share price was $0.20 and its highest was $3.08 in the past 12 months.
What is Atara Biotherapeutics’s market cap?
Currently, no data Available
When is Atara Biotherapeutics’s upcoming earnings report date?
Atara Biotherapeutics’s upcoming earnings report date is May 08, 2024 which is in 20 days.
How were Atara Biotherapeutics’s earnings last quarter?
Atara Biotherapeutics released its earnings results on Mar 28, 2024. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.445 by -$0.115.
Is Atara Biotherapeutics overvalued?
According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
Does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics does not currently pay dividends.
What is Atara Biotherapeutics’s EPS estimate?
Atara Biotherapeutics’s EPS estimate is -$0.26.
How many shares outstanding does Atara Biotherapeutics have?
Currently, no data Available
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Atara Biotherapeutics reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.445. Following the earnings report the stock price went down -1.56%.
Which hedge fund is a major shareholder of Atara Biotherapeutics?
Among the largest hedge funds holding Atara Biotherapeutics’s share is Wexford Capital LP. It holds Atara Biotherapeutics’s shares valued at 15K.
---
Atara Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.43 (699.71% Upside)
$5.43 (699.71% Upside)
Blogger Sentiment
Neutral
GB:0HIY Sentiment 50%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $40.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.68%
12-Months-Change
Fundamentals
Return on Equity
-2014.86%
Trailing 12-Months
Asset Growth
-56.03%
Trailing 12-Months
Company Description
Atara Biotherapeutics
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
---
0HIY Earnings Call
Q3 2023
0:00 / 0:00
---
0HIY Stock 12 Months Forecast
Average Price Target
$5.43
▲(699.71% Upside)
Technical Analysis
Atara Biotherapeutics
―
BioMarin Pharmaceutical
―
Bluebird Bio
―
Crispr Therapeutics AG
―
Gilead Sciences
―
Best Analysts Covering 0HIY
1 Year
1 Year Success Rate
20/40 ratings generated profit
1 Year Average Return
+20.63%
reiterated a buy rating 21 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +20.63% per trade.
---